Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide

Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide - Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of Enzalutamide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019277

Enrollment

Registered

2015-10-08

Start date

2015-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Prostate biopsy before Enzalutamide treatement for CRPC

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Castration resistant prostate cancer patients who are going to receive Enzalutamide treatment are included in this study. Local recurrent cancer is detected by MRI.

Exclusion criteria

Exclusion criteria: Patients who are unable to receive prostate biopsy safely. Pathents with severe side effect by previous prostate biopsy. Allergy to Enzalutamide. Refuse the study. Age is younger than 20 years old.

Design outcomes

Primary

Measure	Time frame
To analyze gene mutation or expression profiles in the local or metastatic biopsy specimens of castration resistant prostate cancer patients. To find novel biomarkers to ecaluate the gene mutation or expression in blood or urine sampls.	—

Countries

Japan

Contacts

Public ContactNaoki Terada

Kyoto University Graduate School of Medicine Urology

nterada@kuhp.kyoto-u.ac.jp075-751-3337

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026